Efficacy and Safety of Durvalumab in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis
- Status
- UNKNOWN
- Phase
- PHASE4
Clinical Trials Related to Durvalumab
Related studies linked through entity extraction aliases.
Sirolimus and Durvalumab for the Treatment of Stage I-IIIA Non-small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Durvalumab and Olaparib for the Treatment of Prostate Cancer in Men Predicted to Have a High Neoantigen Load
- Status
- TERMINATED
- Phase
- PHASE2
DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural Mesothelioma
- Status
- COMPLETED
- Phase
- PHASE3
Intermittent Checkpoint Inhibitor Therapy In Patients With Advanced Urothelial Carcinoma
- Status
- TERMINATED
- Phase
- PHASE2
Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma
- Status
- COMPLETED
- Phase
- PHASE2
DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
AZD6738 Plus Durvalumab in Biliary Tract Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Durvalumab for Advanced Hepatocellular Carcinoma in Patients With Active Chronic Hepatitis B Virus Infection
- Status
- COMPLETED
- Phase
- PHASE2
Assess the Safety of Immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment
- Status
- TERMINATED
- Phase
- PHASE1
Spanish Real World Data on Patients Treated With Durvalumab After Chemoradiotherapy.
- Status
- COMPLETED
- Phase
- N/A
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Platinum-Based Chemotherapy and Durvalumab for the Treatment of Stage IIIB or IV Non-small Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
A Multi-Cancer, Multi-State, Platform Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Pancreatic Adenocarcinoma, Non-Small Cell Lung Cancer and Squamous Cell Carcinoma of the Head and Neck to Correlate Clinical, Molecular and Immunologic Parameters With DNA Methylation
- Status
- WITHDRAWN
- Phase
- PHASE2
A Phase 2 Study of Durvalumab (MEDI4736) and Oleclumab (MEDI9447) in Multi-Cancer Populations With Correlation to Clinical, Molecular and Immunologic Parameters With DNA MethylaTION
- Status
- WITHDRAWN
- Phase
- PHASE2
IPH5201 as Monotherapy or in Combination With Durvalumab +/- Oleclumab in Subjects With Advanced Solid Tumors.
- Status
- COMPLETED
- Phase
- PHASE1
Safety and Tolerance of Epigenetic and Immunomodulating Drugs Combined With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
- Status
- UNKNOWN
- Phase
- PHASE2
Study of Durvalumab Following Radiation Therapy in Patients With Stage 3 Unresectable NSCLC Ineligible for Chemotherapy
- Status
- COMPLETED
- Phase
- PHASE2
Multimodality Treatment in Stage III Non-small Cell Lung Cancer (NSCLC)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2